… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … November 20 at 1:20-2:00 p.m. GMT Presentation at the 1 st RNAEditing Summit During the 1 st RNAEditing Summit to be held …
LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators and pr
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that it intends to offer
… bring a tremendous amount of experience in the fields of RNA-based therapeutics and genetic pediatric diseases. The … of the Company’s novel and proprietary next generation RNAediting technology, Axiomer®, that utilizes endogenous …